AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

In the last year, many AbbVie Inc. insiders sold a substantial stake in the company which may have sparked shareholders' ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...